Home > IP News
ZURICH (Reuters) - Novartis has taken India's Biocon to court for infringing the patent on its diabetes drug Galvus, the Swiss drugmaker said in a statement on Thursday.
The Basel-based firm has filed infringement proceedings and is seeking an injunction against Biocon at Delhi's High Court to try to stop the Indian company launching a generic version of Galvus, also known as vildagliptin.
In a hearing that took place on March 28, the Delhi court ordered that Biocon cannot manufacture, sell or export vildagliptin until the next court hearing, Novartis said in an emailed statement.
"A robust and predictable intellectual property (IP) system is an essential pillar of an innovative life science industry," Novartis said.
To continue reading, click here.
(These latest Intellectual Property (IP) news and events presented here, are prepared and compiled by us, the World Patent & Trademark Law Office (WPTO),for your reference and information)